Summarized below are the abstract titles and presentation times. The ATS abstracts are available online at the conference website at http://conference.thoracic.org. The ATS presentations are embargoed for release at the date/time the data are presented at the conference. Once the posters are public, they will be available on
Session: B49 - Non-tuberculous mycobacterial disease and case reports
Date:
Session time:
Poster 11396: 12-month follow-up data from a phase 2 trial of liposomal amikacin for inhalation (LAI) in patients with refractory nontuberculous mycobacterial (NTM) lung infection
Lead author:
Session: B49 - Non-tuberculous mycobacterial disease and case reports
Date:
Session time:
Poster 5105: Airway deposition and retention of liposomal amikacin for inhalation in patients with pulmonary nontuberculous mycobacterial disease
Lead author:
Session: C57 - Cellular/molecular mechanisms and translational aspects of respiratory infections
Date:
Session time:
Poster 8799: Biodistribution and clearance of liposomal amikacin for inhalation and free amikacin after a single-dose inhalation in rats
Lead author:
Session: D52 - Molecular insight into pulmonary hypertension
Date:
Session time:
Poster 10405: Structure dependent PK profiles of alkyl ester treprostinil prodrugs (TPD) administered via metered dose inhaler to rats
Lead author:
About
"Insmed" and "ARIKAYCE" are the company's trademarks. All other trademarks, trade names or service marks appearing in this press release are the property of their respective owners.
About Nontuberculous Mycobacteria Lung Disease
NTM is a rare and serious disorder associated with increased morbidity and mortality. There is an increasing rate of lung disease caused by NTM and this is an emerging public health concern worldwide. Patients with NTM lung disease may experience a multitude of symptoms such as fever, weight loss, cough, lack of appetite, night sweats, blood in the sputum, and fatigue. Patients with NTM lung disease frequently require lengthy hospital stays to manage their condition. There are no products specifically indicated for the treatment of NTM lung disease in the US,
The prevalence of human disease attributable to NTM has increased over the past two decades. In a decade long study (1997 to 2007), researchers found that the prevalence of NTM in the US is increasing at approximately 8% per year and that NTM patients on
For more information about NTM lung disease, visit NTMfacts.com.
About ARIKAYCE
ARIKAYCE, or liposomal amikacin for inhalation, is a novel, once daily formulation of amikacin that is in late stage clinical development for patients with NTM lung disease. Amikacin solution for parenteral administration is an established drug that is effective against a variety of NTM; however, its use is limited by the need to administer it intravenously and by toxicity to hearing, balance, and kidney function. Insmed's advanced pulmonary liposome technology uses charge neutral liposomes to deliver amikacin directly to the lung where it is taken up by the lung macrophages where the NTM infection resides. This prolongs the release of amikacin in the lungs while minimizing systemic exposure thereby offering the potential for decreased systemic toxicities. ARIKAYCE's ability to deliver high levels of amikacin directly to the lung distinguishes it from intravenous amikacin. ARIKAYCE is administered once daily using an optimized, investigational eFlow® Nebulizer System manufactured by
About PARI Pharma and the eFlow® Electronic Nebulizer
Arikayce is delivered by a novel, inhalation device, the eFlow® Electronic Nebulizer, developed by
